BREAST CANCER RESEARCH AID (BCRA)

Registered charity 1166674 · accounts filings on the Charity Commission register · also known as BCR-UK, BREAST CANCER RESEARCH UK · also registered in Scotland as SC046669 (OSCR)

The charity helps save lives by supporting the ongoing research into breast cancer, and contributing to the further understanding of the disease prevention, diagnosis and treatment by supporting ground-breaking research programmes.

Causes: The Advancement Of Health Or Saving Of Lives · Grant history (this charity is a funder) · website · Get email alerts

Latest income
£123k
Latest spending
£132k
Registered
2016
Accounts read
FY2025

Financial health, per its FY2025 accounts

The accounts state that the charity reported a net deficit of £8,211 for the year, with unrestricted funds decreasing from £81,342 to £73,131. The trustees consider the remaining unrestricted funds of £73,131 to be appropriate to respond to requests for financial support. The charity maintains a reserves policy target of three to six months' expenditure, which the trustees consider has been maintained throughout the year.

Automated summary of the FY2025 accounts; the evidenced findings below carry the verbatim passages.

What the accounts disclose

Reserves policy: between three and six month’s expenditure (held: £73k)
“It is the policy of the Charity that unrestricted funds which have not been designated for a specific use should be maintained at a level equivalent to between three and six month’s expenditure.” — page 4
Per its FY2025 accounts as filed with the Charity Commission.
Payments to trustees: One trustee received £18,000 for administrative services.
“Included in staff costs is payments to one of the Trustees for administrative services to the charity during the year of £18,000 (2024 - £18,000).” — page 11
Per its FY2025 accounts as filed with the Charity Commission.
Related-party transaction: Note 7
“Included in staff costs is payments to one of the Trustees for administrative services to the charity during the year of £18,000 (2024 - £18,000). No Trustees were reimbursed travelling expenses.” — page 11
Per its FY2025 accounts as filed with the Charity Commission.

Accounts independently examined (not a full audit). Discloses 5 of 6 completeness components.

Trustees · trustee networks

Trustee list from the Charity Commission register (current, not historical).

Operates in: Scotland · Throughout England And Wales

Income and spending

Financial year endIncomeSpending
31/03/2025£123k£132k
31/03/2024£129k£127k
31/03/2023£141k£143k
31/03/2022£121k£123k
31/03/2021£76k£50k

Common questions

Is BREAST CANCER RESEARCH AID (BCRA) financially healthy?

Per its FY2025 accounts: The accounts state that the charity reported a net deficit of £8,211 for the year, with unrestricted funds decreasing from £81,342 to £73,131. The trustees consider the remaining unrestricted funds of £73,131 to be appropriate to respond to requests for financial support. The charity maintains a reserves policy target of three to six months' expenditure, which the trustees consider has been maintained throughout the year. Its FY2025 accounts were independently examined.

Funders of similar charities

Funders whose accounts show grants to charities similar to this one (and no recorded grant to this charity) — a starting list for fundraisers.

Charities like this

Semantically similar by activities and financial character, from our analysed corpus. Compare with LADIES FIGHTING BREAST CANCER CHARITABLE TRUST.

Side by side with its peers

CharityIncomeTop pay bandStaff >£60kReserves vs policyFundraising costGoing concern
BREAST CANCER RESEARCH AID (BCRA)£123k—0unclear—no doubt
LADIES FIGHTING BREAST CANCER CHARITABLE TRUST FY2025£233k—0unclear—no doubt
Prevent Breast Cancer FY2025£2.2m——unclear—no doubt
BREAST CANCER UK LIMITED FY2025£2.1m—0above17.7%no doubt
CANCER RESEARCH WALES FY2026£5.9m——unclear—no doubt
AGAINST BREAST CANCER LIMITED FY2024£1.1m—0unclear—no doubt

Each row is that charity’s latest analysed filing; every value is quote-backed on its own page.